NantWorks founder Patrick Soon-Shiong led the round. New investors include AstraZeneca, Lingotto, Teradyne and Strange Ventures, alongside returning investors Casdin Capital, Lux Capital, Fifty Years, Ora Global and Founders Fund. The financing brings Multiply’s total capital raised since 2016 to more than $100 million.
Multiply builds enclosed robotic clusters that connect existing pharmaceutical-production instruments. Robotic arms transfer materials between machines, handle vials and perform operations including stirring and mixing. The company says the platform uses customer process data to learn established workflows without requiring manufacturers to replace their validated instruments.
Customers purchase and operate the systems inside their own facilities. CEO Fred Parietti told Business Insider that Multiply has deployed a high-single-digit number of machines, including systems used by AstraZeneca and Legend Biotech. Each currently costs several million dollars to build, with components sourced through a European supply chain.
Multiply claims its technology can increase throughput by as much as 100 times and reduce cost per dose by 74% compared with manual manufacturing. The company has not published independently audited results, customer-level production data or details of the baseline processes used for those comparisons.
The funding will support additional manufacturing capacity, product development and hiring across engineering, regulatory and commercial teams as Multiply moves from clinical-stage installations toward commercial-scale production.
